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Mario Hebecker,† Joseph J. E. Caesar,x Matthew C. Pickering,{ Kenji Daigo,‖
Takao Hamakubo,‖ Susan M. Lea,x Elena Goicoechea de Jorge,{ and Miha´ly Jo´zsi*,†
The physiological roles of the factor H (FH)-related proteins are controversial and poorly understood. Based on genetic studies, FH-
related protein 5 (CFHR5) is implicated in glomerular diseases, such as atypical hemolytic uremic syndrome, dense deposit disease,
and CFHR5 nephropathy. CFHR5 was also identified in glomerular immune deposits at the protein level. For CFHR5, weak com-
plement regulatory activity and competition for C3b binding with the plasma complement inhibitor FH have been reported, but its
function remains elusive. In this study, we identify pentraxin 3 (PTX3) as a novel ligand of CFHR5. Binding of native CFHR5 to
PTX3 was detected in human plasma and the interaction was characterized using recombinant proteins. The binding of PTX3 to
CFHR5 is of ∼2-fold higher affinity compared with that of FH. CFHR5 dose-dependently inhibited FH binding to PTX3 and also
to the monomeric, denatured form of the short pentraxin C–reactive protein. Binding of PTX3 to CFHR5 resulted in increased
C1q binding. Additionally, CFHR5 bound to extracellular matrix in vitro in a dose-dependent manner and competed with FH for
binding. Altogether, CFHR5 reduced FH binding and its cofactor activity on pentraxins and the extracellular matrix, while at the
same time allowed for enhanced C1q binding. Furthermore, CFHR5 allowed formation of the alternative pathway C3 convertase
and supported complement activation. Thus, CFHR5 may locally enhance complement activation via interference with the
complement-inhibiting function of FH, by enhancement of C1q binding, and by activating complement, thereby contributing
to glomerular disease. The Journal of Immunology, 2015, 194: 4963–4973.
T
he human complement factor H (FH)–related protein 5
(CFHR5) belongs to the FH protein family (1). This pro-
tein family includes two splice variants of the FH gene,
FH and FH-like protein 1 (FHL-1), and five CFHR proteins (2). All
members of this protein family consist of complement control
protein (CCP) domains (also known as sushi domains or short
consensus repeats) and show a high degree of sequence similarity to
each other and to FH. Whereas FH is a well-characterized inhibitor
of the alternative complement pathway, the function of the CFHR
proteins is controversial (2, 3). In general, the CFHR proteins lack
domains and activity related to the complement regulatory CCP1–4
domains of FH. The C-terminal region is highly conserved within
the family: all CFHR proteins possess domains similar to CCPs 19–
20 of FH. Some CFHR proteins, for example, CFHR3, contain
domains with high similarity to CCP domains 6–7 of FH (2).
CFHR5 is a 65-kDa plasma glycoprotein produced in the liver,
with a reported serum concentration of ∼3–6 mg/ml (4). CFHR5
consists of nine CCP domains that are related to CCPs 6–7, CCPs
10–14, and CCPs 19–20 of FH (see Fig. 1A). CFHR5 was originally
isolated from human glomerular complement deposits (1) with an
Ab generated against preparations of a human kidney with mem-
branoproliferative glomerulonephritis (5). Using this Ab, CFHR5
was detected in glomerular immune deposits in several kidney
diseases, for example, membranous nephropathy, IgA nephropathy,
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lupus nephritis, focal glomerular sclerosis, and postinfectious
glomerulonephritis (6). Variations in the CFHR5 gene were also
found in patients with atypical hemolytic uremic syndrome and
membranoproliferative glomerulonephritis type II/dense deposit
disease (7–9). Recently, a subtype of C3 glomerulonephritis was
linked to a mutation and internal duplication in the CFHR5 gene
and this disease entity was termed CFHR5 nephropathy (10).
The function of the CFHR5 protein is not well understood. It was
reported that CFHR5 has cofactor activity for factor I (FI) in the
C3b cleavage and CFHR5 accelerates the decay of the fluid-
phase C3bBb convertase. However, these activities were only
evident at nonphysiological concentrations (4). Analyses of the
structural properties of CFHR protein 1 (CFHR1), CFHR2, and
CFHR5 revealed that these CFHRs form homo- and hetero-
dimers in serum and can deregulate complement by competing
with FH for binding to C3b and surface polyanions (11, 12).
Recently, a hybrid CFHR2–CFHR5 protein was shown to cause
deregulation of complement (13). CFHR5 was also shown to bind
to C-reactive protein (CRP), an acute phase protein belonging to the
family of pentraxins (4).
Pentraxins are pattern recognition molecules of the innate immune
system and have the capacity to activate complement by binding C1q
(14). CRP can interact with several members of the FH protein
family, namely FH, FHL-1, CFHR4, and CFHR5 (4, 15, 16), but the
interaction of FH with the denatured monomeric CRP versus native
pentameric CRP is still a controversial issue (16–20). The long
pentraxin, pentraxin 3 (PTX3), is produced locally by neutrophils,
macrophages, myeloid dendritic cells, fibroblasts, endothelial cells,
and retinal pigment epithelial cells under inflammatory conditions
(21, 22). Its plasma level is ∼2 ng/ml, which can increase to ∼1.5
mg/ml during sepsis, inflammation, and infections (23). PTX3 is
a 45-kDa glycoprotein and forms stable octamers with disulfide
bonds (24). It recruits the complement regulators FH, FHL-1,
CFHR1, and C4b binding protein (25–27). Both CRP and PTX3
can initiate complement activation and, by binding complement
regulators, govern the reaction to opsonization rather than to the lytic
terminal pathway (28). A recent report described PTX3 complexes
that also contain CFHR5 in sepsis serum/plasma samples (29).
The aim of this study was to characterize CFHR5–pentraxin
interactions, as well as interaction with the extracellular matrix that
could be exposed during kidney endothelial injury, and investigate
how they influence the regulatory role of FH and activation of
complement.
Materials and Methods
Proteins, Abs, and sera
Recombinant human FHL-1, CFHR1, CCPs 8–14 of FH (FH8–14), CFHR4A,
and CFHR4B were generated using the pBSV-8His baculovirus expression
vector (30), expressed in Spodoptera frugiperda (Sf9) cells, and purified by
nickel-affinity chromatography as described (31, 32). Recombinant human
CFHR5, PTX3, anti-CFHR5 mAbs and polyclonal Abs, and biotinylated goat
anti-human PTX3 Ab were obtained from R&D Systems (Wiesbaden, Ger-
many). Recombinant mutant CFHR5 with CCPs 1–2 duplicated was produced
as described (11). The N- and C-terminal fragments of PTX3 were obtained
as previously described (29). The C-terminal fragments of the CFHR proteins
were generated as described (11).
Purified human FH, C3, C3b, factor B (FB), factor D, properdin (factor P
[FP]), FI, C1q, recombinant human CRP, goat anti-human FH Ab, goat anti-
human FB Ab, and goat anti-human C1q Ab were obtained from Merck
(Budapest, Hungary). The anti-FH mAb Ab A254 and the anti-FP mAb
A235 were fromQuidel (Biomedica, Budapest, Hungary). MaxGel, the goat
anti-CRP Ab, and the anti–monomeric CRP mAb (mCRP; clone CRP-8)
were from Sigma-Aldrich (Budapest, Hungary). The anti-pentameric CRP
(pCRP) mAb was purchased from antibodies-online.com (Aachen, Ger-
many). HRP-conjugated goat anti-human C3 was from MP Biomedicals
(Solon, OH). HRP-conjugated swine anti-rabbit Igs, rabbit anti-goat Igs,
and goat anti-mouse Igs were from Dako (Hamburg, Germany).
Normal human plasma was collected from healthy individuals after
informed consent and pooled.
Microtiter plate binding assays
To analyze binding of native CFHR5 from human plasma to PTX3, 25%
normal human plasma, diluted in TBS (10 mM Tris, 140 mM NaCl, 2 mM
CaCl2, 1 mM MgCl2 [pH 7.4]), was added for 1 h at 37˚C to wells coated
with 5 mg/ml PTX3 or gelatin. After washing, bound proteins were eluted
from the wells with SDS sample buffer (60 mM Tris base, 1% SDS, 10%
glycerol, bromophenol blue). Eluted proteins were separated on a 10%
SDS-PAGE gel and analyzed by Western blot using CFHR5-specific Ab.
Binding of CFHR5 and FH to PTX3- and gelatin-coated wells was mea-
sured by ELISA using FH Ab and HRP-conjugated anti-goat Ig. TMB Plus
substrate (Kem-En-Tec Diagnostics, Taastrup, Denmark) was used to vi-
sualize binding, and the absorbance was measured at 450 nm.
To compare PTX3 binding by FH family proteins, Costar microtiter plates
(Corning, Corning, NY) were coated with 200 nM each of purified FH,
recombinant CFHR1, CFHR4A, and CFHR5 in TBS (25 ml) overnight at 4˚C.
The wells were washed after each step with TBS containing 0.05% Tween 20.
After blocking with 4% dry milk in TBS for 2 h at 37˚C, 5 mg/ml PTX3 was
added in TBS for 1 h at 37˚C. Bound PTX3 was detected with a biotinylated
anti-PTX3 Ab followed by HRP-conjugated streptavidin. Calcium and pH
dependence of PTX3 binding was analyzed as described previously (27).
To measure PTX3 binding to CFHR protein fragments, wells were coated
with 5 mg/ml proteins, followed by blocking with 3% BSA in TBS and
incubation with 10 mg/ml PTX3. PTX3 binding was detected as described
above.
To compare binding of PTX3 and C3b to the mutant and wild-type
CFHR5, the recombinant proteins were immobilized at 10 mg/ml con-
centration. Binding of 10 mg/ml PTX3 and 10 mg/ml C3b was measured
using the corresponding Abs. To compare binding of wild-type and mutant
CFHR5 from serum, normal serum and patient serum (11) diluted 1:1 in
TBS were applied to wells coated with 10 mg/ml PTX3 and CRP for 30
min at 37˚C. After washing, the eluted proteins were analyzed by Western
blot using polyclonal CFHR5 Ab as described above.
Binding of C1q to PTX3wasmeasured by incubating 10mg/ml C1q added
together with increasing amounts of CFHR5 and FH to wells coated with
5 mg/ml PTX3 for 1 h at 22˚C. C1q binding was detected using anti-C1q. To
measure C1q binding to CFHR5-bound PTX3, microplate wells were coated
with 5 mg/ml recombinant CFHR5, with PTX3, and, as control, with gelatin
and then incubated with 5 mg/ml PTX3 followed by 25 mg/ml or 50 mg/ml
C1q. C1q binding was measured using anti-C1q.
For inhibition assays, wells coated with MaxGel (diluted 1:30 in TBS
containing Ca2+ and Mg2+), PTX3 (30 nM), or CRP (87 nM) were incubated
with 50 mg/ml FH in the absence or presence of increasing concentrations of
CFHR5 for 1 h at 22˚C. FH binding was detected with the mAb A254, which
does not recognize CFHR5. To detect competition between CFHR5 and FH
in serum, heat-inactivated (56˚C, 30 min) human serum was used. Wells
were coated with 10 mg/ml PTX3, 10 mg/ml CRP, and MaxGel diluted 1:30
in Dulbecco’s PBS (DPBS). After blocking with 4% BSA in DPBS, the
wells were incubated for 30 min at 37˚C with 25% heat-inactivated human
serum with or without 0.5 mM CFHR5 and CFHR4A. FH binding was
detected with mAb A254 and the corresponding secondary Ab.
Interaction of CFHR5 with pCRP was measured in TBS containing Ca2+
and Mg2+ and with mCRP, which was generated from commercially avail-
able CRP as described (33), in DPBS (Lonza, Cologne, Germany). CFHR5
and control proteins were immobilized at 5 mg/ml in microplate wells and,
after blocking with 3% BSA in the corresponding buffer, incubated with up
to 50 mg/ml pCRP or mCRP. CRP binding was detected with the goat anti-
human CRP Ab that recognizes both CRP forms (16). In separate assays,
CRP was immobilized in microplate wells at 5 mg/ml in DPBS. Under this
condition most bound CRP decays into the mCRP form (16). After blocking,
300 nM CFHR5 (20 mg/ml) and FH (50 mg/ml) were added for 1 h at 22˚C
and binding was detected using the FH Ab.
Cofactor assay for C3b inactivation
To assay FH cofactor activity on surfaces, wells coated with MaxGel
(diluted 1:30 in TBS containing Ca2+ and Mg2+), gelatin (10 mg/ml),
PTX3 (30 nM), or CRP (87 nM) were preincubated with 20 mg/ml
CFHR5 for 1 h at 22˚C. After washing, 50 mg/ml FH was added for 1 h
at 22˚C, followed by thorough washing. Next, 140 nM C3b and 220 nM FI,
diluted in TBS, were added in 50 ml to the wells and incubated for 1 h at
37˚C. The reactions were stopped by adding reducing SDS sample buffer.
Samples were then loaded onto 10% SDS-PAGE gels, separated by elec-
trophoresis, and subjected to Western blot. C3 fragments were detected
using HRP-conjugated goat anti-human C3 and an ECL detection kit
(Merck).
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Extracellular matrix assays
To study the binding of CFHR5, PTX3, and FH to human extracellular
matrix (ECM), MaxGel diluted 1:50 in TBS was immobilized on microtiter
plate wells overnight at 4˚C and used for subsequent binding assays (as
described above). Endothelial cell–derived ECM was prepared as de-
scribed (25, 27) by culturing HUVEC (American Type Culture Collection;
LGC Promochem, Wesel, Germany) on gelatin-coated 96-well tissue
culture plates (0.2% gelatin) in DMEM (Lonza) supplemented with 10%
FCS, 1% L-glutamine, and 50 mg/ml gentamicin sulfate in a cell incubator
with humidified atmosphere containing 5% CO2 for 7 d at 37˚C. Cells were
washed and detached from the plate by incubation in DPBS containing
10 mM EDTA at 37˚C. Removal of the cells was monitored by microscopy.
The cell-free ECM was washed with TBS and used immediately for
binding assays as described above. The production of ECM by endothelial
cells was confirmed by detecting ECM components after cell detachment,
using Abs against laminin, collagen type IV, and von Willebrand factor
(Sigma-Aldrich).
C3 convertase assays
Formation of the C3bBb alternative pathway C3 convertase on surface-bound
CFHR5 and detection of the C3 convertase components were performed as
previously described (34). The convertase activity was measured by adding
10 mg/ml purified C3 for 1 h at 37˚C and quantifying the generated C3a by
a C3a ELISA kit (Quidel).
Complement activation assays
To measure complement activation due to competition between CFHR5 and
FH for ligand binding, Nunc microplate wells were coated with 10 mg/ml
PTX3, 10 mg/ml CRP, and MaxGel diluted 1:30 in DPBS. After blocking
with 4% BSA in DPBS, 12.5% normal human serum (for PTX3 and CRP)
and 25% normal human serum (for ECM) were added for 30 min at 37˚C,
with or without 20 mg/ml CFHR5 or CFHR4A. Complement activation was
detected by measuring deposition of C3 fragments using HRP-conjugated
goat anti-human C3.
In other experiments, Nuncmicrotiter platewells were coatedwith 5mg/ml
CFHR5, CFHR4A, FH, and human serum albumin (HSA) and, after
blocking with 3% BSA in DPBS, incubated with 10% normal human serum
with or without 5 mM Mg2+-EGTA or 5 mM EDTA for 30 min at 37˚C.
Deposition of C3b, FB, and FP was detected using the corresponding pri-
mary and secondary Abs.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego, CA). A p value ,0.05 was con-
sidered statistically significant.
Results
CFHR5 binds to PTX3
Previously, we showed that serum FH and CFHR1 bind to PTX3
(27). To investigate binding of CFHR5, we incubated human
plasma in PTX3-coated wells and analyzed the bound pro-
teins after elution and SDS-PAGE by Western blotting using
CFHR5-specific Ab. The native CFHR5 protein was detected
by this approach in the PTX3-coated wells but not in gelatin-
coated control wells (Fig. 1B). Direct interaction of CFHR5
with PTX3 was analyzed by ELISA. Recombinant CFHR5
showed dose-dependent binding to PTX3, and the binding of
CFHR5 to PTX3 reached saturation at a lower concentration
compared with the binding of FH (Fig. 1C). To further analyze
this, serial dilutions of PTX3 were applied to CFHR5, immo-
bilized in microplate wells, and the amount of bound PTX3 was
calculated from a standard curve (Fig. 1D). Dose-dependent
binding was observed in the 1–10 nM range; however, avidity
effects complicate affinity determinations because of the octameric
FIGURE 1. CFHR5 interacts with PTX3. (A) Schematic drawing of FH, CFHR5, and CFHR4A. FH is built up of 20 CCP domains, of which CCPs 1–4
mediate complement regulatory activity and CCPs 19–20 mediate surface recognition by FH. The CCP domains of CFHR5, and also CFHR4A, which was
used as control protein in several experiments, are shown aligned with the corresponding most related FH domains. The numbers above the domains indicate
the percentage of amino acid sequence identity between the homologous domains. The mutant CFHR5 protein detected in CFHR5 nephropathy and
containing a duplication of CCPs 1–2 is also shown. CFHR4B consists of CCPs 1 and 6–9 of CFHR4A (not shown). (B) Microplate wells were coated with
gelatin or PTX3 and then incubated with 25% normal human plasma (NHP). After washing, bound proteins were removed by adding SDS sample buffer and
subjected to 10% SDS-PAGE and Western blotting using monoclonal anti-CFHR5. The blot is representative of three experiments. (C) Comparison of
binding of CFHR5 and FH to PTX3. Immobilized PTX3 and gelatin, used as negative control protein, were incubated with the indicated concentrations of
purified FH or recombinant CFHR5. Binding of both proteins was detected by an FH Ab. Data are means 6 SEM derived from four experiments. Both FH
and CFHR5 bound to PTX3 significantly stronger than to gelatin (p , 0.001, two-way ANOVA). (D) Addition of increasing amounts of PTX3 results in
a saturable binding to immobilized CFHR5. Specific binding was measured using a standard curve of PTX3. Data are means 6 SEM from eight
experiments.
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nature of PTX3 and CFHR5 being dimeric, resulting potentially in
multivalent binding.
Characterization of the CFHR5–PTX3 interaction
To compare the binding of PTX3 to CFHR proteins, equimolar
amounts of purified FH and recombinant CFHR1, CFHR4A, and
CFHR5 were immobilized in microplate wells and PTX3 was
added in the fluid phase. CFHR1 showed less PTX3 binding ca-
pacity compared with FH, in agreement with our previous results
(27), whereas CFHR5 showed the strongest binding among the
studied proteins (Fig. 2A). PTX3 binding to CFHR4A was rather
weak, similar to that reported previously for CFHR4B (26).
FIGURE 2. Comparison of the binding of PTX3 with CFHR proteins, and dependence of the PTX3–CFHR5 interaction on calcium concentration and pH.
(A) Binding of PTX3 to recombinant CFHR5 was compared with that of CFHR1, CFHR4A, and FH by ELISA. The FH family proteins and BSA, used as
negative control, were immobilized in equimolar concentrations (200 nM) in microplate wells, and then 5 mg/ml recombinant PTX3 was added for 1 h at
37˚C. PTX3 binding was determined using a polyclonal anti-PTX3 Ab. The values were normalized for FH binding (100%) and show means 6 SD derived
from three independent experiments. **p, 0.01, ***p, 0.001, one-way ANOVA. (B) The binding of PTX3 to immobilized FH and CFHR5 was compared
in DPBS (pH 7.4) with (filled bars) and without (open bars) 1 mM Ca2+. The data are normalized to binding in the presence of Ca2+ (100%) and represent
means6 SD from four experiments. ***p, 0.001, one-way ANOVA. (C) The binding of PTX3 to CFHR5 was compared in TBS with pH 7.4, 6.5, and 5.5.
The data shown are normalized to values obtained with TBS pH 7.4 (100%) and represent means6 SD from five experiments. *p, 0.05, one-way ANOVA.
FIGURE 3. Characterization of the PTX3–CFHR5 interaction. (A) Gelatin, full-length PTX3, and the N- and C-terminal PTX3 fragments were
immobilized in microplate wells (5 mg/ml). Binding of FH (40 mg/ml), FH8-14 (10 mg/ml), and CFHR5 (10 mg/ml) was measured using polyclonal anti-FH
Ab. Data are mean absorbance values 6 SD derived from four independent experiments. **p , 0.01, ***p , 0.001, one-way ANOVA. (B) Binding of
PTX3 to the C-terminal CFHR domains that are the homologs of the PTX3-binding CCP19–20 of FH was measured by ELISA. CCP4–5 of CFHR1, CCP3–
4 of CFHR2, CCP4–5 of CFHR3, CCP8–9 of CFHR4A, CCP8–9 of CFHR5, and CCP19–20 of FH, as well as the full-length FH, CFHR1, CFHR4B,
CFHR5, and HSA proteins as controls, were immobilized at 5 mg/ml concentration in microplate wells. Recombinant PTX3 at 10 mg/ml was added and its
binding was detected as described for Fig. 2. Data are mean absorbance values 6 SD derived from three independent experiments. *p , 0.05, ***p ,
0.001, one-way ANOVA. (C) Binding of PTX3 to the CFHR5 mutant with duplicated CCP1–2 (mutant FH–related protein 5 [mutCFHR5]) was measured
by immobilizing mutCFHR5, and as controls, CFHR5 and gelatin at 10 mg/ml in microplate wells. Binding of 10 mg/ml PTX3, 10 mg/ml C3b, and
a CFHR5-specific polyclonal Ab was measured by ELISA as described inMaterials and Methods. The data are means6 SD derived from four independent
experiments. *p , 0.05, one-way ANOVA. (D) Wells coated with PTX3 (lanes 1–3) and CRP (lanes 4–6) were incubated with 50% normal human serum
(NHS) (lanes 2 and 5) and a patient serum containing both wild-type CFHR5 and the mutCFHR5 (lanes 3 and 6). The bound proteins were analyzed after
elution and 10% SDS-PAGE by Western blotting using polyclonal CFHR5 Ab. Reactivity of the polyclonal Ab with NHS (1 ml, lane 7) and patient serum
(1 ml, lane 8) is shown as a control. The blot is representative of two experiments.
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Because the presence of Ca2+ is required for several interactions
of pentraxins, the role of Ca2+ in the binding of PTX3 to CFHR5
was studied. Similar to FH, CFHR5 showed strongly reduced
PTX3 binding when Ca2+ was absent from the buffer (Fig. 2B).
The binding of PTX3 to FH and FHL-1 was shown to be in-
creased at lower pH (27). In contrast, we found that the binding of
CFHR5 was slightly but significantly reduced at pH 5.5 compared
with the physiological pH (Fig. 2C).
Analysis of binding sites involved in the CFHR5–PTX3
interaction
To determine which domain of PTX3 mediates the binding to
CFHR5, recombinant N- and C-terminal PTX3 fragments were
immobilized on microtiter plates and incubated with recombinant
CFHR5. CFHR5 bound to both the N- and C-terminal parts of
PTX3 (Fig. 3A). FH also bound to both PTX3 fragments, whereas
the control recombinant CCP8–14 domains of FH did not bind to
any PTX3 fragment, in agreement with previous results (26).
Because the CCP19–20 domains of FH were shown to be involved
in binding PTX3 (26, 27), we investigated the capacity of the ho-
mologous CCP8–9 domains of CFHR5, and also the homologous
domains of the other CFHR proteins, to bind PTX3. PTX3 did not
bind to the CFHR5 CCP8–9 fragment, indicating a binding site
outside these domains (Fig. 3B). PTX3 bound to CCP19–20 of FH
and CCP4–5 of CFHR1, as expected from previous studies (26, 27),
but it did not bind to CCP3–4 of CFHR2, CCP4–5 of CFHR3, and
CCP8–9 of CFHR4A (Fig. 3B).
A disease-associated CFHR5 protein contains CCPs 1–2 in two
copies (Fig. 1A). To analyze the role of these domains and the
capacity of this disease-associated CFHR5 mutant (mutant FH–
related protein 5 [mutCFHR5]) in PTX3 binding, the binding of
PTX3 to immobilized recombinant mutCFHR5 protein compared
with wild-type CFHR5 was measured. The mutCFHR5 protein
bound less PTX3 than did the wild-type protein, whereas the
binding of fluid-phase C3b was comparable to both proteins in the
assay (Fig. 3C).
The interaction was confirmed using serum as a source of CFHR5
(Fig. 3D). Normal human serum and a patient serum containing
both wild-type CFHR5 and the mutCFHR5 were incubated in wells
coated with PTX3 and the related short pentraxin CRP. The bound
proteins were analyzed after elution and SDS-PAGE by Western
blotting using polyclonal CFHR5 Ab. Whereas the amount of the
mutCFHR5 was clearly higher in the patient serum compared with
the normal CFHR5 (Fig. 3D, lane 8), a weaker mutCFHR5 band
was observed among both the PTX3- and CRP-bound proteins,
confirming the results obtained with recombinant mutCFHR5.
FIGURE 4. C1q binding to PTX3 in the presence of CFHR5. (A) Binding
of C1q to PTX3 was determined in the presence of increasing concentrations
of CFHR5 and FH in ELISA. C1q binding was detected using C1q Ab. The
normalized values are means 6 SD derived from four independent experi-
ments. *p , 0.05, ***p , 0.001, two-way ANOVA. (B) C1q binds to
CFHR5-bound PTX3. Microplate wells were coated with 5 mg/ml recombi-
nant CFHR5 and, as control, with gelatin, and then sequentially incubated
with 5 mg/ml PTX3 and 25 mg/ml or 50 mg/ml C1q, as indicated. C1q
binding was measured using C1q Ab. The data are means6 SD derived from
four independent experiments. **p, 0.01, ***p, 0.001, one-way ANOVA.
FIGURE 5. CFHR5 competes with FH binding and activity on PTX3.
(A) The binding of 50 mg/ml (∼300 nM) FH to PTX3 was measured in the
presence of increasing concentrations of CFHR5 (up to 20 mg/ml, corre-
sponding to ∼300 nM CFHR5) using an FH-specific mAb for detection.
HSA was used as control protein. The normalized values are means 6 SD
derived from four independent experiments. The binding of FH was sig-
nificantly different in the presence of 20 mg/ml CFHR5 than in the presence
of 20 mg/ml HSA (p = 0.0005, unpaired t test). (B) The cofactor activity of
FH bound to PTX3 for the cleavage of C3b in the presence and absence
of CFHR5 was measured by Western blot as described in Materials and
Methods. Microplate wells were coated with 10 mg/ml PTX3 and incubated
with 50 mg/ml FH with or without 20 mg/ml CFHR5, as indicated below the
blot, and then C3b and FI were added to each well. The molecular mass
marker is indicated on the left, and the C3b chains and the C3b a9-chain
cleavage fragments are indicated on the right. The blot was developed using
HRP-conjugated C3-specific Ab that recognizes C3b and its fragments but
not C3d. The blot is representative of three independent experiments.
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Effect of the ligands C3b and C1q on the CFHR5–PTX3
interaction
The main known CFHR5 ligand is the complement fragment C3b.
Therefore, we studied whether C3b influences the PTX3 binding
capacity of CFHR5. To this end, CFHR5 immobilized in microplate
wells was preincubated with increasing concentrations of C3b.
Then PTX3 was added and PTX3 binding was measured. C3b
showed dose-dependent binding to CFHR5 and it did not influence
the binding of PTX3 (5 mg/ml) to CFHR5 at concentrations up to
50 mg/ml (data not shown).
C1q binding to PTX3 is thought to initiate classical com-
plement pathway activation (35). We investigated whether CFHR5
can interfere with the binding of C1q to PTX3. To this end, wells
coated with PTX3 were preincubated with increasing amounts of
CFHR5 and C1q binding was measured. CFHR5 could partly
inhibit C1q binding to PTX3 (up to ∼50% under the tested ex-
perimental conditions), whereas FH had no inhibitory effect
on C1q binding to PTX3 (Fig. 4A). In a reverse setting, we ana-
lyzed whether CFHR5-bound PTX3 can interact with C1q. C1q
showed binding to CFHR5 that was strongly enhanced by PTX3
bound to CFHR5 (Fig. 4B). Thus, C1q can bind to CFHR5-
bound PTX3.
CFHR5 competes with FH for binding to PTX3
The binding of FH to PTX3 is thought to downregulate PTX3-
induced complement activation (26, 27). Therefore, we assessed
the ability of CFHR5 to interfere with the binding of the comple-
ment inhibitor FH to PTX3. CFHR5 strongly and dose-dependently
inhibited FH binding to PTX3, whereas the control protein HSA
had no effect on this interaction (Fig. 5A). Accordingly, CFHR5
inhibited the cofactor activity of PTX3-bound FH by strongly re-
ducing FH binding to PTX3. When bound to PTX3, FH acted as
a cofactor for the FI-mediated cleavage and inactivation of C3b
(Fig. 5B, lane 2), which was strongly reduced by CFHR5 added in
1:1 molar ratio to FH (300 nM each) (Fig. 5B, lane 3), whereas
CFHR5 itself showed no cofactor activity (Fig. 5B, lane 4).
CFHR5 binds to denatured, monomeric CRP and inhibits FH
binding and cofactor activity
CRP shares a pentraxin domain homologous to that of PTX3. CFHR5
was shown to interact with CRP, but the CRP form that binds to
CFHR5 and the functional consequence of this interaction were not
investigated (4). We therefore set out to characterize the CFHR5–
CRP interaction in more detail. CFHR5 did not bind the native pCRP
in ELISA under our experimental conditions (Fig. 6A), but it readily
interacted with the denatured mCRP (Fig. 6B). The control proteins
FIGURE 6. Interaction of CFHR5 with CRP. (A) FH, CFHR4A, and CFHR5 were immobilized in microplate wells at 5 mg/ml. After blocking, binding of
50 mg/ml pCRP was measured in TBS containing 2 mM CaCl2 and 1 mM MgCl2 using a polyclonal CRP-specific Ab. Data are mean absorbance values 6
SD from three experiments. ***p , 0.001, one-way ANOVA. (B) In parallel experiments, binding of 25 mg/ml mCRP, generated from pCRP by urea/
chelation treatment, was measured in DPBS without Ca2+ using the same polyclonal anti-CRP as in (A). Data are mean absorbance values 6 SD from three
experiments. ***p , 0.001, one-way ANOVA. (C) To measure CFHR5 binding to surface-bound CRP, 5 mg/ml CRP was immobilized in microplate wells,
which results in the generation of mCRP. Equimolar amounts (300 nM) of CFHR5 and FH were added and their binding was detected using FH Ab. Data
are mean absorbance values 6 SD from four experiments. ***p , 0.001, one-way ANOVA. (D) The binding of 50 mg/ml (∼300 nM) FH to CRP,
immobilized in microplate wells, was measured by ELISA in the presence of increasing concentrations of CFHR5 (up to 20 mg/ml, corresponding to ∼300
nM CFHR5) using an FH-specific mAb for detection. HSA was used as control protein. The normalized values are means 6 SD derived from three in-
dependent experiments. The binding of FH was significantly different in the presence of 20 mg/ml CFHR5 than in the presence of 20 mg/ml HSA (p ,
0.0001, unpaired t test). (E) The cofactor activity of FH bound to CRP for the cleavage of C3b in the presence and absence of CFHR5 was measured by
Western blot. Microplate wells were coated with 10 mg/ml CRP and incubated with 50 mg/ml FH with or without 20 mg/ml CFHR5, as indicated below the
blot, and then C3b and FI were added to each well. The blot was developed as described for Fig. 5 and is representative of three independent experiments.
The molecular mass marker is indicated on the left, and the C3b chains and the C3b a9-chain cleavage fragments are indicated on the right.
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used in these experiments, CFHR4A and FH, bound pCRP and
mCRP, respectively, as expected (16). CFHR5 also bound to mCRP
in the reverse setting, when mCRP was generated by immobilization
of pCRP on the ELISA plates (Fig. 6C).
Similar to PTX3, the binding of FH tomCRPwas dose-dependently
inhibited by CFHR5 (Fig. 6D). When bound to mCRP, FH displayed
cofactor activity for the FI-mediated cleavage and inactivation of C3b
(lane 2), which was inhibited by CFHR5 (lane 3) (Fig. 6E). CFHR5
itself showed no cofactor activity under these conditions (Fig. 6E,
lane 4).
CFHR5 binds to ECM, competes with FH, and recruits PTX3
Previously, we showed that FH, FHL-1, and CFHR1 bind to ECM
(27). Therefore, we analyzed the interaction of CFHR5 with the
model ECM MaxGel. The binding of native CFHR5 to MaxGel
from serum could be detected by Western blot (Fig. 7A). Recombi-
nant CFHR5 exhibited a strong, dose-dependent binding to MaxGel
(Fig. 7B). Similarly to the case of pentraxins (Figs. 5, 6), CFHR5
inhibited the surface-associated cofactor activity of FH by com-
peting with its binding to MaxGel (Figs. 7C, 7D). Additionally,
CFHR5, but not FH, FHL-1, and CFHR1, strongly enhanced
binding of PTX3 to both MaxGel and HUVEC-derived ECM
(Fig. 7E). PTX3 had only a minor effect on CFHR5 binding to
ECM (not shown).
CFHR5 competes with FH in serum
To confirm that the observed competition between CFHR5 and FH
occurs also in serum, wells were coated with PTX3, CRP, and
MaxGel and incubated with heat-inactivated serum, which was used
to exclude FH binding through deposited C3 fragments. CFHR5
when added to heat-inactivated serum significantly reduced the
amount of bound FH on PTX3, CRP, and MaxGel (Fig. 8A). As
a negative control, recombinant CFHR4Awas used, which does not
bind well to PTX3 (Fig. 2A), immobilized CRP (Fig. 6) (16), and
MaxGel (27). In line with this, CFHR4A did not inhibit FH binding
to any of these ligands (Fig. 8A).
Additionally, C3 fragment deposition on PTX3, CRP, and
MaxGel was measured in complement active normal serum when
CFHR5 was added to increase its concentration. In all cases, ad-
dition of CFHR5 but not CFHR4A caused increased C3 deposition,
indicating competitive inhibition of FH activity by CFHR5 on these
ligands (Fig. 8B).
The C3bBb alternative pathway C3 convertase assembles on
CFHR5
We have previously shown that CFHR4 can activate complement by
binding C3b and allowing formation of an active C3bBb alternative
pathway C3 convertase (34). We analyzed whether such a C3
convertase can also be formed on CFHR5. To this end, immobilized
FIGURE 7. Interaction of CFHR5 with the extracellular matrix. (A) Microplate wells were coated with MaxGel or HSA and incubated with normal
human serum. After washing, bound proteins were removed by adding SDS sample buffer and subjected to 10% SDS-PAGE and Western blotting using
polyclonal anti-CFHR5. The blot is representative of three experiments. (B) Dose-dependent binding of recombinant CFHR5, added in the indicated
concentrations, to MaxGel and gelatin (both immobilized at 20 mg/ml) was measured by ELISA using polyclonal Ab to human CFHR5. The data are means6
SD of absorbance values derived from four independent experiments. *p , 0.05, **p , 0.01, two-way ANOVA. (C) The binding of 50 mg/ml (∼300 nM) FH
to MaxGel was measured by ELISA in the presence of increasing concentrations of CFHR5 (up to 20 mg/ml, corresponding to ∼300 nM CFHR5) using
an FH-specific mAb for detection. HSAwas used as control protein. The normalized values are means 6 SD derived from three independent experiments.
The binding of FH was significantly different in the presence of 20 mg/ml CFHR5 than in the presence of 20 mg/ml HSA (p = 0.0027, unpaired t test). (D)
The cofactor activity of FH bound to MaxGel for the cleavage of C3b in the presence and absence of CFHR5 was measured by Western blot. Microplate
wells were coated with MaxGel (diluted 1:30) and incubated with 50 mg/ml FH with or without 20 mg/ml CFHR5, as indicated below the blot, and then C3b
and FI were added to each well. The blot was developed as described for Fig. 5 and is representative of three independent experiments. The molecular mass
marker is indicated on the left, and the C3b chains and the C3b a9-chain cleavage fragments are indicated on the right. (E) Binding of 5 mg/ml PTX3 to
MaxGel (open bars) and HUVEC-derived ECM (filled bars) preincubated with the indicated FH family proteins at 20 mg/ml (recombinant CFHR1 and
CFHR5) or 100 mg/ml (recombinant FHL-1 and purified FH) concentration was measured by ELISA as described for Fig. 2. The normalized values are
means 6 SD derived from four independent experiments. **p , 0.01, ***p , 0.001, one-way ANOVA.
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CFHR5 was incubated with C3b, followed by the addition of pu-
rified FB, factor D, and FP. Convertase formation was detected by
measuring the Bb fragment. Similar to CFHR4A, CFHR5 supported
C3bBb formation, but the amount of C3 convertase was less on
CFHR5 compared with CFHR4A (Fig. 9A). The CFHR5-bound
convertase was functional as shown by the generation of C3a af-
ter the addition of purified C3 to the convertase (Fig. 9B). We
detected no binding of purified FB alone to CFHR5. We observed
weak binding of purified FP to CFHR5, which could be an ar-
tifact due to the known in vitro formation of nonphysiological FP
oligomers (Supplemental Fig. 1).
Incubation of CFHR5 with 10% normal human serum supple-
mented with 5 mM Mg2+-EGTA confirmed the generation of the
alternative pathway C3 convertase as measured by deposition of C3,
FB, and FP (Fig. 10). In serum supplemented with 5 mM EDTA,
no complement activation and convertase formation was detected,
as expected. The residual C3 signal on CFHR4A is due to direct
binding of C3 fragments (Fig. 10A).
Discussion
The function of the FH-related proteins is a controversial issue. Most
studies reported lack of FH-like complement–inhibiting activity for
the CFHR proteins at physiological concentrations (11, 12, 34, 36),
as expected from the domain composition of these proteins. How-
ever, weak cofactor activity for CFHR3, CFHR4, and CFHR5 (4,
37) as well as strong cofactor activity for CFHR3 were reported
(38). Complement regulation by other mechanisms, such as in-
hibition of the terminal complement pathway, were reported for
CFHR1 and CFHR2 (39, 40), but others could not detect this
activity (11, 41). Additionally, enhancement of complement acti-
vation by CFHR4 via binding of C3b and CRP was described (32,
34).
Despite the suggested complement-inhibiting function for the
CFHRs, microbes that bound CFHR1, CFHR2, and CFHR5 were
not protected by these proteins from complement attack (42, 43).
Increased expression of CFHRs under infectious conditions (44)
and the described competition of CFHR1 with FH for certain
bacterial ligands (45, 46) and for the major opsonin C3b (11)
indicate that CFHRs may interfere with the regulatory activity of
FH. Cumulatively, these data suggest that instead of inhibition of
complement activation, the CFHRs rather cause enhanced activa-
tion. This could be advantageous to the human host during infec-
tions, as it may help the opsonophagocytic removal of microbes, but
also that of cellular debris under noninfectious conditions.
Depending on the local concentration, oligomeric state, polymor-
phic and mutant variants, and binding strength of FH, CFHRs, and
their ligands, the delicate balance between complement activation/
deregulation and inhibition could be shifted in favor of activation,
resulting in pathologic complement activation.
Although currently there is no convincing evidence for physi-
ologically relevant complement-inhibiting roles of the CFHR
proteins, their association with complement-mediated diseases is
supported by genetic studies (47). Importantly, three recent reports
showed that CFHR1, CFHR2, and CFHR5 deregulate complement
by competing with FH for binding to C3b, and thus they may rather
enhance complement activation in human renal diseases (11–13).
Our present study supports a function of CFHR5 as competitive
FIGURE 8. CFHR5 competes with FH in serum for binding to PTX3, CRP,
and MaxGel and causes enhanced C3 fragment deposition. (A) Wells were
coated with 10 mg/ml PTX3, 10 mg/ml CRP, and MaxGel diluted 1:30 in
DPBS. After blocking, the wells were incubated for 30 min at 37˚C with 25%
heat-inactivated human serum with or without 0.5 mM CFHR5 and CFHR4A.
FH binding was detected with mAb A254 and the corresponding secondary
Ab. The normalized values are means 6 SD derived from three independent
experiments. ***p , 0.001, one-way ANOVA. (B) Nunc microplate wells
were coated with 10 mg/ml PTX3, 10 mg/ml CRP, and MaxGel diluted 1:30 in
DPBS. After blocking, 12.5% normal human serum (for PTX3 and CRP) and
25% normal human serum (for ECM) were added for 30 min at 37˚C, with or
without 20 mg/ml CFHR5 or CFHR4A. Complement activation was detected
by measuring C3 fragment deposition using HRP-conjugated goat anti-human
C3. Data represent mean absorbance values 6 SD from three independent
experiments. **p , 0.01, ***p , 0.001, one-way ANOVA.
FIGURE 9. Assembly of the alternative pathway C3 convertase on
CFHR5. (A) Assembly of the C3bBb convertase on CFHR5. Recombinant
CFHR4A, CFHR5, and, as negative control, HSA were immobilized in
microplate wells, followed by incubation with 10 mg/ml C3b. The alter-
native pathway C3 convertase was built up by adding purified FB, factor D,
and FP for 30 min at 37˚C. The convertase was detected with polyclonal
anti-FB Ab. The data are mean absorbance values 6 SD derived from five
independent experiments. **p , 0.01, ***p , 0.001, one-way ANOVA.
(B) Activity of the CFHR5-bound convertase was measured by adding 10
mg/ml C3 to the wells for 1 h at 37˚C. C3a generation was measured by
Quidel’s C3a ELISA kit. Data are mean absorbance values 6 SD from
three experiments. ***p , 0.001, one-way ANOVA.
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inhibitor of FH and as enhancer of complement activation. We
further investigated the role of CFHR5 in complement activation
and in modulating the activity of FH, which could be particularly
relevant during acute phase response (with increase in pentraxin
concentrations) and endothelial injury.
We identified novel CFHR5 ligands, such as PTX3, modified
CRP, and ECM, which are likely relevant in disease-associated
roles of CFHR5. CFHR5 was implicated in particular in various
kidney pathologies based on genetic and protein-level studies (6–8,
10, 11, 48). Our data suggest that not only binding of C3b or C3b
fragments (such as iC3b) by CFHR5 could be important in the
context of diseases, but likely also interactions with molecules,
such as pentraxins that are upregulated during inflammation and
renal endothelial damage, and with host surfaces such as the
ECM. This is supported by recent proteomics studies, which
identified both CFHR5 and PTX3 as glomerular ECM-associated
proteins (49, 50).
PTX3 is produced locally at the site of inflammation. Elevated
PTX3 levels were described in various infectious and inflammatory
diseases, including chronic kidney disease (23, 51, 52). Both
protective and detrimental effects of PTX3 have been described,
such as in postischemic renal injury (23, 53, 54). Systemic PTX3
concentration of up to ∼1.5 mg/ml was reported, indicating that lo-
cally at inflammatory sites it can reach much higher concentrations,
similar to those used in this study, suggesting that the studied PTX3–
CFHR5 interaction has physiological relevance.
A previous study described cofactor activity for CFHR5, but rather
high concentrations of the protein were required for this function (4).
In our present study, we found no cofactor activity of CFHR5 at the
studied physiologically relevant concentrations (Figs. 5–7). How-
ever, physiological amounts of CFHR5 significantly competed with
FH in binding to the pentraxins PTX3 and CRP, as well as to ECM.
Importantly, this competition could be detected in serum and caused
enhanced complement activation (Fig. 8). This represents an indi-
rect means by which CFHR5 deregulates complement, namely, not
via direct competition with FH for C3b, but by interfering with FH
binding to its other physiological ligands. These data suggest that
depending on the FH-binding surfaces and ligands, as well as on
local FH and CFHR5 concentrations, CFHR5 can fine-tune local
complement regulation by competing with FH.
The binding of PTX3 to CFHR5 is the strongest among the tested
FH family proteins; this explains the strong inhibitory effect of
CFHR5 on FH binding to PTX3 (Figs. 1, 2, 5). The PTX3–CFHR5
interaction is strongly reduced in Ca2+-free buffer (Fig. 2), similar to
the PTX3 binding to FH, FHL-1, and CFHR1, as reported previ-
ously (26, 27).
Our data show that at reduced pH, which might occur at sites of
inflammation, the binding of PTX3 to CFHR5 is reduced. We have
previously shown that at lower pH the binding of PTX3 to C1q and
CFHR1 is unchanged but the binding of PTX3 to the complement
inhibitors FH, FHL-1, and C4b-binding protein is increased (27).
Collectively, these data suggest that under such conditions com-
plement inhibition is preferred, because the binding of the com-
plement inhibitors increases and that of the deregulator CFHR5
decreases.
The PTX3 binding site in CFHR5 appears not to be homologous to
the two identified PTX3 binding sites in FH, that is, FH domains CCP7
and CCP19–20. CCP1–2 of CFHR5 are the dimerization domains
and very different structurally and functionally from CCP6–7 of FH.
CCP2 of CFHR5 is very similar to CCP2 of CFHR1 (∼85% amino
acid sequence identity); however, we showed previously that PTX3
binds to CFHR1 via the C terminus of CFHR1 (27). We tested the
C-terminal domains of all of the five human CFHR proteins, and only
CCP4–5 of CFHR1 bound PTX3 under our experimental conditions.
The CCP8–9 domains of CFHR5 did not bind PTX3 (Fig. 3). Ad-
ditionally, these domains were shown to bind C3b, and C3b did not
influence PTX3 binding by CFHR5 in our experiments (not shown).
Moreover, the binding site for the related pentraxin CRP was local-
ized to CCPs 3–7 of CFHR5 (4). Thus, it is likely, but needs to be
tested in the future, that the PTX3-binding site also resides within
these middle domains of CFHR5. Additionally, the tested disease-
associated mutant CFHR5 protein, in which the two N-terminal
domains are duplicated, showed reduced PTX3-binding capacity in
comparison with the wild-type protein (Fig. 3). This could be caused
by the restricted availability of PTX3-binding sites in the mutant,
which has an increased tendency to form oligomers (11).
The known PTX3 ligand C1q could partially inhibit PTX3
binding to CFHR5, but not to FH, indicating partially overlapping
binding sites or conformational changes of PTX3 when bound to
C1q. However, CFHR5-bound PTX3 could still strongly bind C1q
(Fig. 4). We observed C1q binding to CFHR5 alone, which was
strongly and significantly enhanced by PTX3.
Interaction of CFHR5 with CRP was first described by McRae
et al. (4) but the type of CRP that binds CFHR5 was not studied. FH
binds preferentially to the modified, monomeric form of CRP via
domains CCP7, CCPs 8–11, and CCPs 19–20 (15–17), and at acute
phase CRP concentrations it was reported to interact also with the
FIGURE 10. Complement activation by CFHR5. CFHR5 was immobi-
lized on microplate wells and incubated with 10% normal human serum in
5 mM Mg2+-EGTA buffer to allow only alternative pathway activation or
with 10% serum containing 5 mM EDTA to inhibit complement activation.
Deposition of (A) C3b, (B) FB, and (C) properdin (FP) was detected using
the corresponding Abs. Immobilized CFHR4Awas used as positive control
and FH and HSAwere used as negative controls. The data are means6 SD
derived from three independent experiments. **p , 0.01, ***p , 0.001,
one-way ANOVA.
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native pentameric form of CRP (18). In contrast, CFHR4 binds
primarily to the native pCRP (16, 32). In our assays, CFHR5 bound
strongly to mCRP, whereas the binding to pCRP was minor (Fig. 6).
CFHR5 also strongly and dose-dependently bound toMaxGel, in
contrast to the relatively weak binding of FH (27). Accordingly,
CFHR5 efficiently inhibited the binding and cofactor activity of
FH on this ECM (Fig. 7). CFHR5, alone among the investigated
FH family proteins, recruited PTX3 to the ECM. These results are
in line with recent proteomics data demonstrating the association
of both CFHR5 and PTX3 with glomerular EC-derived ECM (49,
50), and they suggest that CFHR5 enhances local complement
activation via these interactions.
We also studied the direct role of CFHR5 in complement acti-
vation. In our recent study on CFHR4, we showed that C3b binding
to CFHR4 can result in the assembly of the alternative pathway C3
convertase and activation of C3 (34). In our present study, we found
that CFHR5 can similarly promote C3 convertase formation and
alternative pathway activation, albeit the effect was weaker com-
pared with CFHR4 (Figs. 9, 10). This activity stands in contrast to
the complement alternative pathway inhibitory role of FH.
During kidney endothelial injury, host ligands that are newly
exposed (ECM) or the concentration of which is increased (pen-
traxins) may result in the increased binding of CFHR5 to the site of
injury. The oligomeric state of CFHR5 and CRP can further fine-tune
these interactions, but this needs to be characterized in more detail.
In summary, we show that in addition to competing for C3b
binding with FH as reported recently, CFHR5 may promote com-
plement activation and complement-mediated damage/inflammation
through three mechanisms: 1) by preventing the binding of the
complement inhibitor FH to PTX3, CRP, and ECM; 2) by allowing
increased binding of the complement activation initiator molecule
C1q; and 3) by supporting the assembly of the alternative pathway
C3 convertase C3bBb. These functions may explain in part the
disease-associated role of CFHR5.
Acknowledgments
We thank the Department of Infection Biology, Leibniz Institute for Natural
Product Research and Infection Biology, for access to equipment.
Disclosures
The authors have no financial conflicts of interest.
References
1. McRae, J. L., P. J. Cowan, D. A. Power, K. I. Mitchelhill, B. E. Kemp,
B. P. Morgan, and B. F. Murphy. 2001. Human factor H-related protein 5 (FHR-5).
A new complement-associated protein. J. Biol. Chem. 276: 6747–6754.
2. Jo´zsi, M., and P. F. Zipfel. 2008. Factor H family proteins and human diseases.
Trends Immunol. 29: 380–387.
3. Skerka, C., Q. Chen, V. Fremeaux-Bacchi, and L. T. Roumenina. 2013. Com-
plement factor H related proteins (CFHRs). Mol. Immunol. 56: 170–180.
4. McRae, J. L., T. G. Duthy, K. M. Griggs, R. J. Ormsby, P. J. Cowan, B. A. Cromer,
W. J. McKinstry, M. W. Parker, B. F. Murphy, and D. L. Gordon. 2005. Human
factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity,
binds heparin and C-reactive protein, and associates with lipoprotein. J. Immunol.
174: 6250–6256.
5. Murphy, B. F., and A. J. d’Apice. 1988. Identification of the components of
glomerular immune deposits using monoclonal antibodies. Pathology 20: 130–136.
6. Murphy, B., T. Georgiou, D. Machet, P. Hill, and J. McRae. 2002. Factor H-
related protein-5: a novel component of human glomerular immune deposits.
Am. J. Kidney Dis. 39: 24–27.
7. Abrera-Abeleda, M. A., C. Nishimura, J. L. Smith, S. Sethi, J. L. McRae,
B. F. Murphy, G. Silvestri, C. Skerka, M. Jo´zsi, P. F. Zipfel, et al. 2006. Var-
iations in the complement regulatory genes factor H (CFH) and factor H related
5 (CFHR5) are associated with membranoproliferative glomerulonephritis type
II (dense deposit disease). J. Med. Genet. 43: 582–589.
8. Monteferrante, G., S. Brioschi, J. Caprioli, G. Pianetti, P. Bettinaglio, E. Bresin,
G. Remuzzi, and M. Noris. 2007. Genetic analysis of the complement factor H
related 5 gene in haemolytic uraemic syndrome. Mol. Immunol. 44: 1704–1708.
9. Westra, D., K. A. Vernon, E. B. Volokhina, M. C. Pickering, N. C. van de Kar, and
L. P. van den Heuvel. 2012. Atypical hemolytic uremic syndrome and genetic
aberrations in the complement factor H-related 5 gene. J. Hum. Genet. 57: 459–464.
10. Gale, D. P., E. G. de Jorge, H. T. Cook, R. Martinez-Barricarte, A. Hadjisavvas,
A. G. McLean, C. D. Pusey, A. Pierides, K. Kyriacou, Y. Athanasiou, et al. 2010.
Identification of a mutation in complement factor H-related protein 5 in patients
of Cypriot origin with glomerulonephritis. Lancet 376: 794–801.
11. Goicoechea de Jorge, E., J. J. Caesar, T. H. Malik, M. Patel, M. Colledge,
S. Johnson, S. Hakobyan, B. P. Morgan, C. L. Harris, M. C. Pickering, and
S. M. Lea. 2013. Dimerization of complement factor H-related proteins modu-
lates complement activation in vivo. Proc. Natl. Acad. Sci. USA 110: 4685–4690.
12. Tortajada, A., H. Ye´benes, C. Abarrategui-Garrido, J. Anter, J. M. Garcı´a-
Ferna´ndez, R. Martı´nez-Barricarte, M. Alba-Domı´nguez, T. H. Malik,
R. Bedoya, R. Cabrera Pe´rez, et al. 2013. C3 glomerulopathy-associated CFHR1
mutation alters FHR oligomerization and complement regulation. J. Clin. Invest.
123: 2434–2446.
13. Chen, Q., M. Wiesener, H. U. Eberhardt, A. Hartmann, B. Uzonyi,
M. Kirschfink, K. Amann, M. Buettner, T. Goodship, C. Hugo, et al. 2014.
Complement factor H-related hybrid protein deregulates complement in dense
deposit disease. J. Clin. Invest. 124: 145–155.
14. Bottazzi, B., A. Doni, C. Garlanda, and A. Mantovani. 2010. An integrated view
of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28:
157–183.
15. Jarva, H., T. S. Jokiranta, J. Hellwage, P. F. Zipfel, and S. Meri. 1999. Regulation
of complement activation by C-reactive protein: targeting the complement in-
hibitory activity of factor H by an interaction with short consensus repeat
domains 7 and 8–11. J. Immunol. 163: 3957–3962.
16. Mihlan, M., M. Hebecker, H. M. Dahse, S. Ha¨lbich, M. Huber-Lang, R. Dahse,
P. F. Zipfel, and M. Jo´zsi. 2009. Human complement factor H-related protein 4
binds and recruits native pentameric C-reactive protein to necrotic cells. Mol.
Immunol. 46: 335–344.
17. Hakobyan, S., C. L. Harris, C. W. van den Berg, M. C. Fernandez-Alonso,
E. G. de Jorge, S. R. de Cordoba, G. Rivas, P. Mangione, M. B. Pepys, and
B. P. Morgan. 2008. Complement factor H binds to denatured rather than to
native pentameric C-reactive protein. J. Biol. Chem. 283: 30451–30460.
18. Okemefuna, A. I., R. Nan, A. Miller, J. Gor, and S. J. Perkins. 2010. Comple-
ment factor H binds at two independent sites to C-reactive protein in acute phase
concentrations. J. Biol. Chem. 285: 1053–1065.
19. Hammond, D. J., Jr., S. K. Singh, J. A. Thompson, B. W. Beeler, A. E. Rusin˜ol,
M. K. Pangburn, L. A. Potempa, and A. Agrawal. 2010. Identification of acidic
pH-dependent ligands of pentameric C-reactive protein. J. Biol. Chem. 285:
36235–36244.
20. Singh, S. K., A. Thirumalai, D. J. Hammond, Jr., M. K. Pangburn, V. K. Mishra,
D. A. Johnson, A. E. Rusin˜ol, and A. Agrawal. 2012. Exposing a hidden func-
tional site of C-reactive protein by site-directed mutagenesis. J. Biol. Chem. 287:
3550–3558.
21. Deban, L., S. Jaillon, C. Garlanda, B. Bottazzi, and A. Mantovani. 2011. Pen-
traxins in innate immunity: lessons from PTX3. Cell Tissue Res. 343: 237–249.
22. Woo, J. M., M. Y. Kwon, D. Y. Shin, Y. H. Kang, N. Hwang, and S. W. Chung.
2013. Human retinal pigment epithelial cells express the long pentraxin PTX3.
Mol. Vis. 19: 303–310.
23. Daigo, K., A. Mantovani, and B. Bottazzi. 2014. The yin-yang of long pentraxin
PTX3 in inflammation and immunity. Immunol. Lett. 161: 38–43.
24. Inforzato, A., C. Baldock, T. A. Jowitt, D. F. Holmes, R. Lindstedt,
M. Marcellini, V. Rivieccio, D. C. Briggs, K. E. Kadler, A. Verdoliva, et al. 2010.
The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer
with two binding sites for FGF2. J. Biol. Chem. 285: 17681–17692.
25. Braunschweig, A., and M. Jo´zsi. 2011. Human pentraxin 3 binds to the com-
plement regulator c4b-binding protein. PLoS ONE 6: e23991.
26. Deban, L., H. Jarva, M. J. Lehtinen, B. Bottazzi, A. Bastone, A. Doni,
T. S. Jokiranta, A. Mantovani, and S. Meri. 2008. Binding of the long pentraxin
PTX3 to factor H: interacting domains and function in the regulation of com-
plement activation. J. Immunol. 181: 8433–8440.
27. Kopp, A., S. Strobel, A. Tortajada, S. Rodrı´guez de Co´rdoba, P. Sa´nchez-Corral,
Z. Proha´szka, M. Lo´pez-Trascasa, and M. Jo´zsi. 2012. Atypical hemolytic ure-
mic syndrome-associated variants and autoantibodies impair binding of factor H
and factor H-related protein 1 to pentraxin 3. J. Immunol. 189: 1858–1867.
28. Agrawal, A., P. P. Singh, B. Bottazzi, C. Garlanda, and A. Mantovani. 2009.
Pattern recognition by pentraxins. Adv. Exp. Med. Biol. 653: 98–116.
29. Daigo, K., N. Yamaguchi, T. Kawamura, K. Matsubara, S. Jiang, R. Ohashi,
Y. Sudou, T. Kodama, M. Naito, K. Inoue, and T. Hamakubo. 2012. The pro-
teomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates
the interaction with azurocidin 1 and other components of neutrophil extra-
cellular traps. Mol. Cell. Proteomics 11: M111.015073. doi:10.1074/mcp.
M111.015073.
30. K€uhn, S., and P. F. Zipfel. 1995. The baculovirus expression vector pBSV-8His
directs secretion of histidine-tagged proteins. Gene 162: 225–229.
31. Castiblanco-Valencia, M. M., T. R. Fraga, L. B. Silva, D. Monaris, P. A. Abreu,
S. Strobel, M. Jo´zsi, L. Isaac, and A. S. Barbosa. 2012. Leptospiral immunoglobulin-
like proteins interact with human complement regulators factor H, FHL-1, FHR-1,
and C4BP. J. Infect. Dis. 205: 995–1004.
32. Hebecker, M., A. I. Okemefuna, S. J. Perkins, M. Mihlan, M. Huber-Lang, and
M. Jo´zsi. 2010. Molecular basis of C-reactive protein binding and modulation of
complement activation by factor H-related protein 4.Mol. Immunol. 47: 1347–1355.
33. Mihlan, M., S. Stippa, M. Jo´zsi, and P. F. Zipfel. 2009. Monomeric CRP con-
tributes to complement control in fluid phase and on cellular surfaces and
increases phagocytosis by recruiting factor H. Cell Death Differ. 16: 1630–1640.
4972 CFHR5 BINDS PTX3 AND ECM AND MODULATES COMPLEMENT ACTIVATION
34. Hebecker, M., and M. Jo´zsi. 2012. Factor H-related protein 4 activates complement
by serving as a platform for the assembly of alternative pathway C3 convertase via
its interaction with C3b protein. J. Biol. Chem. 287: 19528–19536.
35. Nauta, A. J., B. Bottazzi, A. Mantovani, G. Salvatori, U. Kishore, W. J. Schwaeble,
A. R. Gingras, S. Tzima, F. Vivanco, J. Egido, et al. 2003. Biochemical and functional
characterization of the interaction between pentraxin 3 and C1q. Eur. J. Immunol. 33:
465–473.
36. Timmann, C., M. Leippe, and R. D. Horstmann. 1991. Two major serum com-
ponents antigenically related to complement factor H are different glycosylation
forms of a single protein with no factor H-like complement regulatory functions.
J. Immunol. 146: 1265–1270.
37. Hellwage, J., T. S. Jokiranta, V. Koistinen, O. Vaarala, S. Meri, and P. F. Zipfel. 1999.
Functional properties of complement factor H-related proteins FHR-3 and FHR-4:
binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett.
462: 345–352.
38. Fritsche, L. G., N. Lauer, A. Hartmann, S. Stippa, C. N. Keilhauer, M. Oppermann,
M. K. Pandey, J. Ko¨hl, P. F. Zipfel, B. H. Weber, and C. Skerka. 2010. An im-
balance of human complement regulatory proteins CFHR1, CFHR3 and factor H
influences risk for age-related macular degeneration (AMD). Hum. Mol. Genet. 19:
4694–4704.
39. Eberhardt, H. U., D. Buhlmann, P. Hortschansky, Q. Chen, S. Bo¨hm, M. J. Kemper,
R. Wallich, A. Hartmann, T. Hallstro¨m, P. F. Zipfel, and C. Skerka. 2013. Human
factor H-related protein 2 (CFHR2) regulates complement activation. PLoS ONE 8:
e78617.
40. Heinen, S., A. Hartmann, N. Lauer, U. Wiehl, H. M. Dahse, S. Schirmer, K. Gropp,
T. Enghardt, R. Wallich, S. Ha¨lbich, et al. 2009. Factor H-related protein 1 (CFHR-
1) inhibits complement C5 convertase activity and terminal complex formation.
Blood 114: 2439–2447.
41. Strobel, S., C. Abarrategui-Garrido, E. Fariza-Requejo, H. Seeberger, P. Sa´nchez-
Corral, and M. Jo´zsi. 2011. Factor H-related protein 1 neutralizes anti-factor H
autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 80: 397–404.
42. Hammerschmidt, C., T. Hallstro¨m, C. Skerka, R. Wallich, B. Stevenson,
P. F. Zipfel, and P. Kraiczy. 2012. Contribution of the infection-associated
complement regulator-acquiring surface protein 4 (ErpC) to complement resis-
tance of Borrelia burgdorferi. Clin. Dev. Immunol. 2012: 349657.
43. Siegel, C., T. Hallstro¨m, C. Skerka, H. Eberhardt, B. Uzonyi, T. Beckhaus, M. Karas,
R. Wallich, B. Stevenson, P. F. Zipfel, and P. Kraiczy. 2010. Complement factor H-
related proteins CFHR2 and CFHR5 represent novel ligands for the infection-
associated CRASP proteins of Borrelia burgdorferi. PLoS ONE 5: e13519.
44. Na¨rkio¨-Ma¨kela¨, M., J. Hellwage, O. Tahkokallio, and S. Meri. 2001. Complement-
regulator factor H and related proteins in otitis media with effusion. Clin. Immunol.
100: 118–126.
45. Haupt, K., P. Kraiczy, R. Wallich, V. Brade, C. Skerka, and P. F. Zipfel. 2007.
Binding of human factor H-related protein 1 to serum-resistant Borrelia burg-
dorferi is mediated by borrelial complement regulator-acquiring surface pro-
teins. J. Infect. Dis. 196: 124–133.
46. Reuter, M., C. C. Caswell, S. Lukomski, and P. F. Zipfel. 2010. Binding of the
human complement regulators CFHR1 and factor H by streptococcal collagen-
like protein 1 (Scl1) via their conserved C termini allows control of the com-
plement cascade at multiple levels. J. Biol. Chem. 285: 38473–38485.
47. Jo´zsi, M., and S. Meri. 2014. Factor H-related proteins. Methods Mol. Biol.
1100: 225–236.
48. Vernon, K. A., D. P. Gale, E. G. de Jorge, A. G. McLean, J. Galliford,
A. Pierides, P. H. Maxwell, D. Taube, M. C. Pickering, and H. T. Cook. 2011.
Recurrence of complement factor H-related protein 5 nephropathy in a renal
transplant. Am. J. Transplant. 11: 152–155.
49. Byron, A., M. J. Randles, J. D. Humphries, A. Mironov, H. Hamidi, S. Harris,
P. W. Mathieson, M. A. Saleem, S. C. Satchell, R. Zent, et al. 2014. Glomerular
cell cross-talk influences composition and assembly of extracellular matrix. J.
Am. Soc. Nephrol. 25: 953–966.
50. Lennon, R., A. Byron, J. D. Humphries, M. J. Randles, A. Carisey, S. Murphy,
D. Knight, P. E. Brenchley, R. Zent, and M. J. Humphries. 2014. Global analysis
reveals the complexity of the human glomerular extracellular matrix. J. Am. Soc.
Nephrol. 25: 939–951.
51. Suliman, M. E., M. I. Yilmaz, J. J. Carrero, A. R. Qureshi, M. Saglam,
O. M. Ipcioglu, M. Yenicesu, M. Tong, O. Heimb€urger, P. Barany, et al. 2008.
Novel links between the long pentraxin 3, endothelial dysfunction, and albu-
minuria in early and advanced chronic kidney disease. Clin. J. Am. Soc. Nephrol.
3: 976–985.
52. Tong, M., J. J. Carrero, A. R. Qureshi, B. Anderstam, O. Heimb€urger, P. Ba´ra´ny,
J. Axelsson, A. Alvestrand, P. Stenvinkel, B. Lindholm, and M. E. Suliman.
2007. Plasma pentraxin 3 in patients with chronic kidney disease: associations
with renal function, protein-energy wasting, cardiovascular disease, and mor-
tality. Clin. J. Am. Soc. Nephrol. 2: 889–897.
53. Chen, J., M. M. Matzuk, X. J. Zhou, and C. Y. Lu. 2012. Endothelial pentraxin 3
contributes to murine ischemic acute kidney injury. Kidney Int. 82: 1195–1207.
54. Lech, M., C. Ro¨mmele, R. Gro¨bmayr, H. Eka Susanti, O. P. Kulkarni, S. Wang,
H. J. Gro¨ne, B. Uhl, C. Reichel, F. Krombach, et al. 2013. Endogenous and
exogenous pentraxin-3 limits postischemic acute and chronic kidney injury.
Kidney Int. 83: 647–661.
The Journal of Immunology 4973
